Gene Express has a BCR-ABL1 quantification test that is designed to help healthcare professionals optimize outcomes in response to imatinib (Gleevec®) treatment for Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) patients. In order to have effective control of CML, the patient must maintain a three-log reduction in BCR-ABL1 mRNA levels. A 3.3-fold increase in expression from baseline is a basis in which the physician would change the treatment regimen.
StaRT-PCR™ BCR-ABL test:
Measures the Major breakpoint of BCR b2a2 and b3a2; Major (p210) translocation breakpoint
Requires whole blood or bone marrow specimens
Test Description:
The StaRT-PCR™ BCR-ABL test measures the BCR-ABL mRNA in blood. For this test total RNA from whole blood is reverse transcribed to cDNA with oligo dT primers and this cDNA is quantitatively calibrated such that the amount of ACTB in the cDNA sample is equal to the amount of ACTB internal standard in the SMIS™. All subsequent high-throughput StaRT-PCR reactions contain the calibrated cDNA, SMIS and primers specific for BCR-ABL, ACTB or an endogenous control gene (ABL, BCR, GUS, or GAPDH). Data is analyzed as an odds ratio and reported as the number of BCR-ABL transcription molecules per 106 endogenous control gene (ACTB, ABL, BCR, GUS, or GAPDH).